The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 19 September 2006, www.theannals.com, DOI 10.1345/aph.1H037.
 The Annals of Pharmacotherapy: Vol. 40, No. 10, pp. 1814-1821. DOI 10.1345/aph.1H037
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brousil, J. A
Right arrow Articles by Schlein, A. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brousil, J. A
Right arrow Articles by Schlein, A. L

NEUROLOGY

Cladribine: An Investigational Immunomodulatory Agent for Multiple Sclerosis

Julie A Brousil, PharmD BCPS

Assistant Professor of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, MO

Russel J Roberts, PharmD

Assistant Professor of Pharmacy Practice, St. Louis College of Pharmacy

Amanda L Schlein

PharmD Student, St. Louis College of Pharmacy

Reprints: Dr. Brousil, Department of Pharmacy Practice, St. Louis College of Pharmacy, 4588 Parkview Place, St. Louis, MO 63110-1088, fax 314/446-8500, jbrousil{at}stlcop.edu

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of cladribine, a purine analog undergoing Phase III trials for approval of its use in the treatment of multiple sclerosis (MS).

DATA SOURCES: A MEDLINE search (1966-September 2006) was conducted using the key words cladribine and multiple sclerosis. No limits were placed on the search.

STUDY SELECTION AND DATA EXTRACTION: Studies and review articles related to cladribine and MS were reviewed. The trials examining the role of cladribine in MS were analyzed.

DATA SYNTHESIS: Cladribine is a purine analog that demonstrates lymphocytotoxic activity. Recent data suggest that cladribine may have a role in the treatment of relapsing-remitting and the progressive forms of MS. In these studies, cladribine has shown mixed results in decreasing neurologic disability, as measured by various rating scales, but has consistently shown positive results in reducing the number of enhancing lesions, which reflects a measure of disease activity. To date, there is one ongoing study examining the role of oral cladribine in the treatment of relapsing-remitting MS. The incidence of adverse effects with cladribine has been significantly greater than with placebo, with the most common being myelosuppression.

CONCLUSIONS: While data do not support its use as a first-line MS treatment, cladribine may be a promising agent for refractory patients with secondary progressive MS. Further studies are warranted.

Key Words: cladribine, multiple sclerosis

Published Online, September 19, 2006. www.theannals.com, DOI 10.1345/aph.1H037

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-06-024-H01


This article has been cited by other articles:


Home page
 Arch NeurolHome page
J. A. Cohen
Emerging Therapies for Relapsing Multiple Sclerosis
Arch Neurol, July 1, 2009; 66(7): 821 - 828.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.